Patent intelligence · US
US 9855252
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
Patent details — US 9855252
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 2, 2018
- Expiration
- Dec 28, 2037
- Applicant
- PALVELLA THERAPEUTICS, INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/436, A61K31/4745, A61K9/0014
Quick answer
US 9855252 (Methods of treating keratin hyperproliferation disorders using mTOR inhibitors) is held by PALVELLA THERAPEUTICS, INC.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PALVELLA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/436, A61K31/4745, A61K9/0014, A61K9/0019, A61K9/0053
More from PALVELLA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12329748
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 12268673
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11679101
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11617742
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
granted -
US 11135204
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11000513
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10722499
Anyhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10172789
Compositions for transdermal delivery of mTOR inhibitors
granted
Frequently asked questions
What is US patent 9855252?
US 9855252 (Methods of treating keratin hyperproliferation disorders using mTOR inhibitors) is held by PALVELLA THERAPEUTICS, INC.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9855252?
PALVELLA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 9855252 expire?
Our index shows an expiration date of Dec 28, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.